METHODS: We identified candidate markers using mRNA expression patterns from laser-capture microdissected prostate tissue and confirmed tissue expression using immunohistochemistry (IHC) for the subset of candidates having commercial antisera. We analyzed tissue extracts with tandem mass spectrometry (MS/MS) and measured blood concentrations using immunoassays and MS/MS of trypsin-digested, immunoextracted peptides.
RESULTS: We selected 35 novel candidate prostate adenocarcinoma biomarkers. For all 13 markers having commercial antisera for IHC, tissue expression was confirmed; 6 showed statistical discrimination between nondiseased and malignant tissue, and only 5 were detected in tissue extracts by MS/MS. Sixteen of the 35 candidate markers were successfully assayed in blood. Four of 8 biomarkers measured by ELISA and 3 of 10 measured by targeted MS showed statistically significant increases in blood concentrations of advanced prostate cancer cases, compared with controls.
CONCLUSION: Seven novel biomarkers identified by gene expression profiles in prostate tissue were shown to have statistically significant increased concentrations in blood from men with advanced prostate adenocarcinoma compared with controls: apolipoprotein C1 (APOC1), asporin (ASPN), cartilage oligomeric matrix protein (COMP), chemokine (C-X-C motif) ligand 11 (CXCL11), CXCL9, coagulation factor V (F5), and proprotein convertase subtilisin/kexin 6 (PCSK6).
Written by:
Klee EW, Bondar OP, Goodmanson MK, Dyer RB, Erdogan S, Bergstralh EJ, Bergen HR 3rd, Sebo TJ, Klee GG. Are you the author?
Department of Health Sciences Research.
Reference: Clin Chem. 2012 Jan 12. Epub ahead of print.
doi: 10.1373/clinchem.2011.171637
PubMed Abstract
PMID: 22247499
UroToday.com Prostate Cancer Section
